Company: CERO
Filing Date: 2025-06-30
Form Type: 8-K
Source: 0001213900-25-059738
Chunk: 3

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-06-30
Form: 8-K
Item: Item 9.01
Chunk 3
---
Item 9.01

Financial Statements and Exhibits.

(d)

  Exhibit Number      Description                                                                                                                                                                                           
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  3.1†                Certificate of Designation of Preferences, Rights and Limitations of the Series D Convertible Preferred Stock, dated April 22, 2025 (incorporated by reference to Exhibit 3.1 to the Company’s Cu...  
  10.1†               Securities Purchase Agreement, dated of April 21, 2025, by and among CERo Therapeutics Holdings, Inc., and the investors signatory thereto (incorporated by reference to Exhibit 10.1 of the Comp...  
  10.2*†              Form of Amendment to the Securities Purchase Agreement.                                                                                                                                               
  104                 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.                                                                                               

  Certain portions of this document that constitute confidential                 

  Filed herewith.  

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

                           CERO THERAPEUTICS HOLDINGS, INC.                               
  Date: June 30, 2025      By:                                   /s/ Chris Ehrlich        
                                                                 Chris Ehrlich            
                                                                 Chief Executive Officer